Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
for
Metastatic Pancreatic Ductal Adenocarcinoma,
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute
Sex: All
Age: 18+
Code: NCT07214298
Phase1, Phase2, Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma
for
Pancreatic Ductal Adenocarcinoma
Location: Houston TX
Sponsor: The University of Texas Health Science Center, Houston
Sex: All
Age: 18+
Code: NCT06831136
Phase2, Recruiting
Interested in new metastatic pancreatic adenocarcinoma trials?
Get alerts for new trials in your area by subscribing now
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
for
Solid Tumors
Location: Boston MA, Lake Success NY, The Bronx NY, New York NY,
Sponsor: Incyte Corporation
Sex: All
Age: 18+
Code: NCT07522073
Phase3, Recruiting
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
for
Pancreatic Ductal Adenocarcinoma (PDAC)
Location: New York NY, Philadelphia PA, Jacksonville FL,
Sponsor: BicycleTx Limited
Sex: All
Age: 18+
Code: NCT07450859
Phase2, Recruiting
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
for
Pancreatic Ductal Adenocarcinoma
Location: Bay Shore NY, New Hyde Park NY, Mount Kisco NY,
Sponsor: Northwell Health
Sex: All
Age: 18+
Code: NCT07163273
Phase2, Recruiting
CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC)
for
Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma,
Location: London
Sponsor: John Lenehan
Sex: All
Age: 18+
Code: NCT06393400
Phase1, Recruiting
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
for
Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC,
Location: Boston MA, New Haven CT, East Brunswick NJ,
Sponsor: Revolution Medicines, Inc.
Sex: All
Age: 18+
Code: NCT07621718
Phase3, Recruiting
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Location: Hackensack NJ, Philadelphia PA, Grand Rapids MI,
Sponsor: Context Therapeutics Inc.
Sex: All
Age: 18+
Code: NCT06756035
Phase1, Recruiting
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
for
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma,
Location: Toronto, Dallas TX, San Antonio TX
Sponsor: Auricula Biosciences Inc.
Sex: All
Age: 18+
Code: NCT07148128
Phase1, Phase2, Recruiting
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
for
Pancreatic Ductal Adenocarcinoma (PDAC)
Location: Boston MA, Worcester MA, New York NY, Philadelphia PA,
Sponsor: SOFIE
Sex: All
Age: 18+
Code: NCT07217717
Phase3, Recruiting
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
for
Pancreatic Cancer, Metastatic,
Location: New York NY, Summit NJ, Maumee OH
Sponsor: Engeneic Pty Limited
Sex: All
Age: 18+
Code: NCT07049055
Phase1, Phase2, Recruiting
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
for
Locally Advanced Pancreatic Adenocarcinoma,
Location: Long Branch NJ, New York NY, Livingston NJ,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04172532
Phase1, Phase2, Recruiting
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors